

icpm **20th**
International Conference
on Pharmaceutical Medicine

Hybrid Meeting 19-21 October 2022

SNFCC, Athens – Greece

Final Programme & Abstract Book

**What lies
ahead in
Pharmaceutical
Medicine**

www.icpm2022.gr



Join an agile global community pursuing innovative medicines development and reflect on Pharmaceutical Medicine in 2030.



www.icpm2022.gr

icpm

CONTENTS

04	WELCOME NOTE
05	GENERAL INFORMATION
08	AUSPICES - SPONSORS
09	SCIENTIFIC PROGRAMME
11	OCTOBER 19, 2022
18	OCTOBER 20, 2022
26	OCTOBER 21, 2022
31	SPEAKERS' LIST
39	ABSTRACT BOOK
58	AUTHORS' INDEX

WELCOME NOTE

Dear colleagues,

2022 is a special year. We are celebrating the long-awaited return of the 20th ICPM since the last one in 2018. It is also the first time that ICPM is accessible both on-site and on-line, ensuring you can access the very latest science and research updates, from wherever you are.

We are delighted to welcome you to a live, interactive hybrid conference on what lies ahead in Pharmaceutical Medicine to meet, learn from and exchange views with renowned academics, researchers, scientists, clinical investigators, regulators, health policy experts, bioethicists, R&D experts, Patient Advocates and Pharmaceutical Medicine Leaders.

Global R&D and New Technologies ecosystem special guests with Pharmaceutical Medicine experts convene to discuss with invited executives from WMA, CIOMS, EUPATI, PharmaTrain, European Research Council, Swiss Clinical Trials Organization, FPM and other international societies on current and emerging trends in biomedical research, precision medicine, advanced therapies, new technologies, evolving research governance and contemporary ethical challenges.

ELEFI & IFAPP as cohosts are warmly welcoming you to an in-depth exploration of Pharmaceutical Medicine future through ICPM 2022 works and offer you exclusive access to discussions with experts, international networks as well as opportunities to connect with distinguished speakers, colleagues, and like-minded scientists.

Again, we welcome you in Athens for a unique learning journey, to enlighten your professional perspective on what lies ahead in Pharmaceutical Medicine.

On behalf of the ICPM 2022 Organizing Committee

Dr Varvara (Barbara) Baroutsou, *Internist, GFMD, EMAUD ELEFI President IFAPP President Elect*
Dr Marco Romano, *MD, PhD, GFMD, IFAPP President*

GENERAL INFORMATION

DATE AND VENUE

The 20th International Conference on Pharmaceutical Medicine – ICPM 2022 is a hybrid meeting organised during the 19th until the 21st of October 2022 at the Book Castle (lobby area of the National Library of Greece), Stavros Niarchos Foundation Cultural Center (SNFCC), Sygrou Avenue 364, 17674 Kallithea, Athens, Greece.

The Stavros Niarchos Foundation Cultural Center is a multifunctional and environmentally sustainable education, arts, and recreation complex which comprises of the 210,000 m² Stavros Niarchos Park, the new, state-of-the-art facilities of the National Library of Greece (NLG) and the Greek National Opera (GNO). URL: www.SNF.org

OFFICIAL LANGUAGE

English is the conference's official language.

REGISTRATION

Delegates may register upon arrival at the Secretariat desk during the Conference.

On-site registration fees

ELEFI/IFAPP members

Physical presence	320€
Virtual attendance	180€

ELEFI/IFAPP non-members

Physical presence	400€
Virtual attendance	250€

Students

Students / Post-graduate students (physical presence)	140€
Students / Post-graduate students (virtual attendance)	50€

All above prices include VAT 24%.

*Members of the Press can register for free provided that they present a Press ID (or other means of certification) at the Conference Secretariat.

GENERAL INFORMATION

CONFERENCE SECRETARIAT

Conference Secretariat is located at the entrance of the Book Castle, SNFCC.

Opening Hours:

Wednesday, October 19: 8:00-19:30

Thursday, October 20: 7:30-19:30

Friday, October 21: 8:30-19:30

Conference material – badges and programme - will be collected at the Conference Secretariat. Please show your passport (or other document of ID) for identification. Access to the Conference Hall and areas at all times will be allowed only to visitors wearing the official conference badge.

CONTACT DETAILS

CONGRESS SECRETARIAT

MINDVIEW

59, Mousson Str., 11524, Athens, Greece

Tel.: +30 210 6231305

Email: info@icpm2022.gr

URL: www.mind-view.gr

SPEAKERS' READY AREA

A Speakers' Ready area will be available throughout the Conference next to the Conference Secretariat. Speakers are requested to hand-in their presentations (CD, USB-key) at least 1 hour before the beginning of their session.

INTERNET ACCESS

Password-free Wi-Fi network is available in the Book Castle premises.

GENERAL INFORMATION

CERTIFICATE OF ATTENDANCE

Certificates of attendance will be provided.

CME-CPD CREDITS

The Panhellenic Medical Association awards 22 Continuing Medical Education (CME) and Continuing Professional Development (CPD) credits as per UEMS-EACCME criteria. Certificates of attendance with CME-CPD credits will be administered to medical doctors provided that they attended at 60% of the scientific programme.

AUSPICES & SPONSORS

UNDER THE AUSPICES



SPONSORS

sanofi



PROGRAMME

www.icpm2022.gr



PROGRAMME

OCTOBER 19, 2022 - DAY 1

PRE-ICPM 2022 MEETING SESSIONS

MAIN HALL – HYBRID

08:30-10:00 **EU CTR Greece Workshop: IMPLEMENTATION ACHIEVEMENTS & CHALLENGES**

Chairs: Eugenia Fouza, Varvara Baroutsou

European Union Clinical Trials Regulation Workshop with Greek stakeholders:

- EU CTR Country Requirements from Ministry of Health, **Ioannis Kotsiopoulos**
- EU CTR Regulatory considerations, **Leonidas Klironomos**
- EU CTR National Ethics Committee for Clinical Trials considerations, **Theofilos Kolettis**
- EU CTR Hellenic Association of Clinical Research Organizations (HACRO) considerations, **Evangelia Koraki**

Discussion

10:00-10:30 BREAK

10:30-12:00 **Round table: TRANSLATIONAL RESEARCH AND PRECISION MEDICINE PROJECTS**

Chair: Vangelis Manolopoulos

Speakers:

- Hellenic Sepsis Study Group Research, **Evangelos J. Giamarellos-Bourboulis**
- Biomedical Research Foundation of the Academy of Athens Research, **Constantin Tamvakopoulos**

PROGRAMME

- Development of small molecule neurotrophin mimetics against neurodegenerative diseases, Theodora Calogeropoulou

Discussion

END OF PRE-ICPM 2022 MEETING SESSIONS

11:00 REGISTRATIONS

12:00-13:00 WELCOME LUNCH

PROGRAMME

OCTOBER 19, 2022 - DAY 1

MAIN HALL – HYBRID

13:00-14:00

OFFICIAL OPENING

Chairs: Varvara Baroutsou, Marco Romano

Officials addresses:

- **Mina Gaga**, Alternate Minister of Health, Ministry of Health, Greece
- **Meletios Athanasios Dimopoulos**, Rector of the National and Kapodistrian University of Athens
- **Katerina Koutsogianni**, Former President, Vice President, Greek Patients Association

Greek Pharmaceutical Industry stakeholders' addresses:

- **Markos Ollandezos**, Scientific Director, Panhellenic Pharmaceutical Association
- **George Tousimis**, Vice President Greece, Pharma Innovation Forum

International stakeholders' addresses:

- **Lembit Rägo**, Secretary-General, Council for International Organizations of Medical Sciences - CIOMS
- **Dr Steffen Thirstrup**, European Medicines Agency Chief Medical Officer

14:00-14:30

BREAK

14:30-15:00

Keynote speech: THE POST-COVID ERA OF DRUG DEVELOPMENT

Speaker: Achilleas Gravanis

Chair: Varvara Baroutsou

PROGRAMME

- 15:00-16:30** **Round table: THE IMPACT OF THE EUROPEAN CLINICAL TRIALS REGULATION ON GLOBAL CLINICAL DEVELOPMENT**
Chair: Ingrid Klingmann
- Speakers:**
- Will the EU Clinical Trial Regulation make Europe a more attractive region for global sponsors of clinical trials? **Silvia Garcia**
 - Will the new EU regulatory framework for trials in different vulnerable populations set the standard for more diversity?
Derick Mitchell
 - Will the EU become the driver for transparency of clinical trial results? **Anne-Sophie Henry-Eude**
- 16:30-17:00** **BREAK**
- 17:00-18:00** **Session: PATIENT AND PUBLIC INVOLVEMENT (PPI) IN MEDICINES R&D: LETS WALK THE TALK**
Chair: Cordula Landgraf
- Speakers:**
- PROMs as foundation of patient-centric clinical research,
Christoph Meier
 - Empowering patients: patient involvement in the whole life cycle of a medicinal product—overview & case study, **Jan Geissler**
- 18:00-18:30** **Dialogue: BIOMEDICAL RESEARCH FOR GLOBAL PUBLIC INTEREST**
Chair: Marco Romano
- Discussants: Andreas Papapetropoulos, Varvara Baroutsou**
-

PROGRAMME

18:30 -19:00 **Lecture: OBESITY, CLINICAL BURDEN AND RELATED R&D**
Speaker: Georgios Rompolas
Chair: Christina Kanaka-Gantenbein

20:00-21:00 **CONFERENCE RECEPTION**

OCTOBER 19, 2022 - DAY 1

PARALLEL HALL – ONLY VIRTUAL

11:00-12:00 **Session: UKRAINIAN WAR CRISIS IMPACT ON CLINICAL TRIALS:
ETHICAL ASPECTS AND PATIENT RIGHTS**
Chair: Sandor Kerpel-Fronius

Speakers:

- Francis P. Crawley
- Chieko Kurihara

16:45-17:15 **Lecture: PATIENTS INVOLVEMENT IN POLICY DECISION MAKING –
THE ROLE OF QUANTITATIVE PATIENT PREFERENCES**
Speaker: Eugena Stamuli
Chair: Shehzad Ali

17:15-18:00 **Session: FACULTY OF PHARMACEUTICAL MEDICINE, UK**
Chair: Brigitte Franke-Bray

Speakers:

- From Training to Trusting; Specialty Curriculum in Pharmaceutical Medicine, 2002-2022, Peter Stonier & Jaya Chidambaram

PROGRAMME

18:00-19:00 **Oral Presentations & e-posters session—North & South America, West Africa & Western Europe**
Chairs: Maria Polydorou, Eleonora Sarikou

ORAL PRESENTATIONS

Pharmaceutical Medicine

OP01 **Educational Program to Brazilian Parliament during COVID-19 Pandemic**

H.G. Osório¹, E.F. Motti², C. Schmidt³, M.V. Lima⁴, S.M. Dainesi¹

¹Brazilian Association of Pharmaceutical Medicine (SBMF)

²GFMD, Trials & Training Consult

³Tigermed Latin America

⁴GFMD, Blau Farmacêutica

Pharmaceutical Medicine

OP02 **Results of the first edition of a Medical Information in the Pharmaceutical Industry University Expert Course in Spain**

Lo Re Daniele

Medical Affairs Chiesi Spain

Pharmaceutical Medicine

OP03 **The Importance of Latin America in Global Clinical Trials: Expanding Clinical Research Beyond Borders**

Marlene Teresa Llópiz Avilés

Global Oversight Director for PPD

Regulatory Science, Regulatory Affairs, Ethical, Legal, Social related issues

OP04 **Post-trial responsibilities, 15 years of discussion**

Sonia Mansoldo Dainesi

PROGRAMME

Brazilian Association of Pharmaceutical Medicine – SBMF

- OP05** **Patient Centricity in Research & Development and Health Technology Assessment**
Access to Pediatric/Adolescent Medicinal Products in Greece
A. Margetis¹, C. Kani¹, A. Chantzaras¹, V. Koutsouris², F. Bacopoulou¹
¹Health Technology Assessment and Reimbursement Committee,
Ministry of Health, Athens, Greece
²Ministry of Health, Athens, Greece

e-POSTER PRESENTATIONS

- PP01** **Patient Centricity in Research & Development and Health Technology Assessment**
Evaluation of consumers' knowledge, beliefs and risk assessment regarding protein
Paraskevi Basdeki¹, Yiota Athanassopoulou¹, Georgia-Eirini Deligiannidou¹, Diamanto Lazari², Christos Kontogiorgis¹, Theodoros Constantinides¹
¹Laboratory of Hygiene and Environmental Protection, Democritus University of Thrace, Alexandroupolis, Greece
²Department of Pharmacognosy-Pharmacology, School of Pharmacy, Faculty of Health Sciences Aristotle University of Thessaloniki, Thessaloniki, Greece
- PP02** **Pharmaceutical Medicine**
How the pharmaceutical medicine world was affected by the COVID-19 Pandemic: A look back
Marlene Teresa Llópiz Avilés
Global Oversight Director for PPD

PROGRAMME

OCTOBER 20, 2022 - DAY 2

MAIN HALL – HYBRID

08:00-09:00 **Oral presentations & e-posters session—Eastern Europe, East Africa, Middle East, Asia, Australia & New Zealand**
Chairs: Grigorios Agkyralidis, Grigorios Rombopoulos

ORAL PRESENTATIONS

Patient Safety & Pharmacovigilance

OP06 **First-line Treatments for Kidney Cancer and Second-line Treatments for Urothelial Cancer: Systematic Review, Meta-analysis of Safety, Cost Analysis**

K.A. Nikolaou¹, C. Kani², F. Bacopoulou^{2,3}, S.L. Markantonis¹

¹Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece

²University Research Institute of Maternal and Child Health & Precision Medicine, and UNESCO Chair in Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

³Center for Adolescent Medicine and UNESCO Chair in Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Pharmaceutical Medicine

OP07 **Early selection of oral formulation acceptability with a scientifically sound composite endpoint assessment method – An efficient strategy to optimize paediatric medicines development**
Viviane Klingmann¹, Sibylle Reidemeister², Ingrid Klingmann³, Manfred Wargenau⁴

PROGRAMME

¹Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany

²Novartis Pharma AG, Global Drug Development /Technical Research & Development, Basel, Switzerland

³Pharmaplex bv, Wezembeek-Oppem, Belgium

⁴M.A.R.C.O. GmbH & Co. KG, Institute for Clinical Research and Statistics, Düsseldorf, Germany

Regulatory Science, Regulatory Affairs, Ethical, Legal, Social related issues

OP08 Gaps and challenges raised by the digital technology use in the pharmaceutical industry

Georgia Livieri^{1,4}, Eleni Mangina², Evangelos Protopapadakis³, Andrie Panayiotou⁴

¹Ethics Research Associate, Cardiovascular Epidemiology and Genetics Research Lab

²College of Science, UCD College of Science, Dublin, Ireland

³National and Kapodistrian University of Athens, Faculty of Philosophy, Athens, Greece

⁴Cyprus International Institute for the Environmental and Public Health, Faculty of Health Sciences, Limassol, Cyprus

RWD / Real World Evidence/ Big Data/ Pharmacoepidemiology

OP09 Real-World Data study on the use of psychiatric drugs in Greece: Investigating the impact of COVID-19 pandemic in mental health

Foteini Dermiki-Gkana, Panagiotis Nikolaos Lalagkas, Christos Kontogiorgis, Theodoros Constantinides

Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece

PROGRAMME

Translational Research & Precision Medicine

- OP10 Value Creation in Cell and Gene Therapies from a Health-Economic Perspective

Daniela Fazzotta, Thomas D. Szucs, Annette Mollet
Faculty of Medicine, University of Basel, Switzerland

e-POSTER PRESENTATIONS

Patient Centricity in Research & Development and Health Technology Assessment

- PP03 Medicinal Products Assessed by the Health Technology Assessment Committee in Greece over 4 years (2018-2022)

A. Chantzaras¹, A. Margetis¹, C. Kani¹, V. Koutsiouris², F. Bacopoulou¹
¹*Health Technology Assessment and Reimbursement Committee, Ministry of Health, Athens, Greece*
²*Ministry of Health, Athens, Greece*

Translational Research & Precision Medicine

- PP04 Health Technology Assessment of two CAR T-cell-based Therapies, Tisagenlecleucel and Axicabtagene Ciloleucel, for the Treatment of Patients with Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphomas

M. Kokkali¹, A. Tsonis¹, C. Kani², F. Bacopoulou^{2,3}, S.L. Markantonis¹
¹*Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece*
²*University Research Institute of Maternal and Child Health & Precision Medicine, and UNESCO Chair in Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece*
³*Center for Adolescent Medicine and UNESCO Chair in Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece*

PROGRAMME

09:00-10:30 **Round table: CLINICAL DATA FOR SAFETY AND PERFORMANCE OF MEDICAL DEVICES (MD) TO OBTAIN MARKET AUTHORIZATION APPROVAL**

Chair: **Ghazaleh Gouya**

Speakers:

- Design of clinical MD investigations and approvable endpoints, **Andreas Beust**
- How much clinical data from Medical Device studies is enough for CE mark? **Shayesteh Fürst-Ladani**
- Guidance documents, **Tom Melvin**

10:30-11:00 **BREAK**

11:00-12:30 **Round table: INSTITUTIONAL RESEARCH GOVERNANCE**

Chairs: **Chieko Kurihara, Takis Vidalis**

Speakers:

- Association for the Accreditation of Human Research Protection Programs (AAHRPP): Institutional governance for protecting research participants, including IRB, **Elyse I. Summers**
- CIOMS Principles of Good Governance for Research Institutions (PGGRI), for research integrity, **Dominique Sprumont**
- Governance of biobank (and health database), under the Bioethics and Safety Act in Korea, **Ilhak Lee**

12:30-13:30 **Session: RWD TRENDS IN PHARMACOEPIDEMIOLOGY AND OPPORTUNITIES FOR RWE**

Chairs: **Brigitte Franke-Bray, Elena Panitti**

PROGRAMME

Speakers:

- Quality in RWD Initiative in Austria, **Johannes Pleiner-Duxneuner**
- MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions, **David Brown**
- A vision for use of real-world evidence in EU medicines regulation: the DARWIN EU network, **Juan Jose Abellan**

13:30-14:30 **LUNCH BREAK**

14:30-16:00 **Round table: NEWLY EMERGING ETHICAL ISSUES WITH DATA DRIVEN RESEARCH AND DATA SHARING**

Chairs: **Kotone Matsuyama, Varvara Baroutsou**

Speakers:

- The WMA's Declaration of Taipei, the EU's GDPR, and the EMA's Policy 0070: The Impact of Ethics, Law, and Policy on Data Sharing Practices in Europe, **Francis P. Crawley**
- Current situation and issues with the Data driven Research in Japan, **Chieko Kurihara**
- Current situation and issues with the Data driven Research in US, **Laura Biven**

16:00-16:30 **BREAK**

16:30-18:00 **Round table: PAEDIATRIC MEDICINAL PRODUCTS – STILL A MATTER OF DISCUSSION**

Chair: **Birka Lehmann**

Speakers:

- Clinical trials with minors - report from the c4c project, **Heidrun Hildebrand**
-

PROGRAMME

- Patients/Parents involvement in development of medicinal products, **Dimitrios Athanasiou**
- Extrapolation – a concept to avoid unnecessary clinical trials in minors, **Silke Gastine**
- The experience of the European Paediatric Translational Research Infrastructure (EPTRI), **Donato Bonifazi**

18:00-19:00 **Round table: PROFESSIONAL DEVELOPMENT IN PHARMACEUTICAL MEDICINE - SHAPING YOUR CAREER IN PHARMACEUTICAL MEDICINE**

Chairs: Annette Mollet, Marco Romano

Speakers:

- **Kataryna Uspenska**
- **Nikolaos Tsokanas**
- **Ricardo Gaminha Pacheco**
- **Enrica Alteri**

PROGRAMME

OCTOBER 20, 2022 - DAY 2

PARALLEL HALL – ONLY VIRTUAL

11:00-12:30 **Round table: CONTINUING EDUCATION IN PHARMACEUTICAL MEDICINE**

Asian expectations to new education and training for all in Pharmaceutical Medicine

Chairs: Victoria Elegant, Kyoko Imamura

Speakers:

- Expectations in Medical Affairs, **Matt Britland**
- PCPM course as our future educational platform to learn pharmaceutical medicine, **Jonas Policarpio**
- PharmaTrain course (CoE course recognized by PharmaTrain), **Kotone Matsuyama**
- MAPS interests and potential collaboration in education & certification, **Victoria Elegant**

13:30-14:30 **LUNCH BREAK**

14:30-16:00 **Round table: CURRENT CHALLENGES & TRENDS IN HEALTH TECHNOLOGY ASSESSMENT FOR PATIENT ACCESS**

Supporting Future EU HTA system under the new HTA Regulation

Chairs: Kostas Athanasakis, Flora Bacopoulou

Speakers:

- **Mihai Rotaru**
 - **Roisin Adams**
-

PROGRAMME

16:30-17:00 **Session: THE SELECTION OF KEY PERFORMANCE INDICATORS FOR AN ECONOMIC EVALUATION OF AI TECHNOLOGIES: THE CASE OF HOSMARTAI**

Chair: Markos Ollandezos

Speaker:

■ 'Smart Hospital' with Artificial Intelligence Technologies
(HosmartAI), **Magda Chatzikou**

PROGRAMME

OCTOBER 21, 2022 - DAY 3

MAIN HALL - HYBRID

- 09:00-09:30 **Hellenic Biocluster: GREEK START UP INNOVATION IN HEALTH AS A LEVER FOR R&D GROWTH**
Speaker: Stamatiki Kritas
Chair: Grigorios Rombopoulos
- 09:30-11:00 **Dialogue: MEDICAL AFFAIRS ON EVOLVING MEDICAL LEADERSHIP, STRATEGIES AND UPSKILLING IN THE DIGITAL ERA**
Chairs: Athanasios Chaniotis, Nikolaos Tsokanas
- Discussants:
■ Alex Moulis
■ Grigorios Rombopoulos
■ Thanassis Kotsanis
- 11:00-11:30 **BREAK**
- 11:30-13:00 **Round table: ARTIFICIAL INTELLIGENCE AND MODERN TRENDS IN PHARMACOVIGILANCE AND ACTIVE SAFETY SURVEILLANCE**
Chairs: Georgia Gkegka, Christina Tsoungkou
- Speakers:
■ Active Safety Surveillance, Pantelis Natsiavas
■ Artificial Intelligence applications in Pharmacovigilance, Karthick Sukumaran
- Commentator: Adamantia Maniatakou
- 13:00-14:00 **LUNCH BREAK**
-

PROGRAMME

- 13:00-14:00 IFAPP HoD & General Assembly
- 14:00-14:30 Nomination of President Elect 2022 and ICPM 2024
- 14:30-16:00 BREAK
- 16:00-17:30 Round table: POST AUTHORIZATION COVID-19 VACCINES SAFETY AND PHARMACOEPIDEMIOLOGY STUDIES
Chair: Christos Kontogiorgis
- Speakers:
- Monitoring the safety and effectiveness of COVID-19 vaccines - The European perspective, Luca Giraldi
 - Methodological aspects of COVID-19 vaccine safety assessment, Olaf Klungel
 - SARS-CoV-2 vaccine safety and hesitancy in Greece: Beyond the (absence of) data, a community perspective, Georgios Pappas
- 17:30-18:30 Dialogue: DIGITAL HEALTH, EMR & CLINICAL RESEARCH: WHERE WE ARE AND WHERE WE WILL GO
Chairs: Konstantina Papageorgiou, Varvara Baroutsou
- Discussants:
- Haralambos Karanikas
 - Vera Vazaiou
 - Aggelina Mavraki
- 18:30-19:00 Keynote speech: DEVELOPMENT OF NOVEL GENETIC TOOLS IN BIOMEDICAL RESEARCH
Speaker: Nektarios Tavernarakis
- Chair: Varvara Baroutsou

PROGRAMME

OCTOBER 21, 2022 - DAY 3

PARALLEL HALL – ONLY VIRTUAL

- 10:30-11:00 **Lecture: SYSTEMS BIOINFORMATICS IN PHARMACOLOGY. REAL WORLD APPLICATIONS FROM THE IMPRES CENTER OF EXCELLENCE**
Speaker: **Nikolas D. Dovrolis**
Chair: **Christina Dalla**
- 11:00-11:30 **Lecture: THE SCIENCE OF SCIENCE COMMUNICATION**
Speaker: **Peter Hovstadius**
Chair: **Anna Jurczynska**
- 11:30-13:00 **Round table: MODERN CLINICAL TRIALS & FUTURE RESEARCH TRENDS**
Chairs: **Stefanos Tarazis, Nikos Dedes**
- Speakers:
- Latest artificial intelligence trends in clinical research, **Dimitris Agrafiotis**
 - Decentralized Clinical Trials, **Clare Campbell, Robin Marcus**
 - Patient recruitment & engagement in clinical trials, **Melisa Harris**
- 14:00-15:30 **Dialogue: PATIENT ENGAGEMENT PROGRAMMES**
Chairs: **Effie Simou, Ioannis Petrovas**
- Discussants:
- **Persephone Augoustides-Savvopoulou**
 - **Dimitris Kontopidis**
-


PROGRAMME

- 15:45-17:15 **IFAPP Workshop on future revision of the Declaration of Helsinki -
Dialogue with WMA**
Chair: Chieko Kurihara
Speaker: Jack Resneck

Commentator: Otmar Kloiber

SPEAKERS' LIST

www.icpm2022.gr



SPEAKERS' LIST

Juan Jose Abellan	Data Analytics and Methods Task Force, Scientific Lead for DARWIN EU, EMA
Roisin Adams	MPharm, MSc, PhD, Head of HTA Strategy and External Engagement NCPE, Full Member of the EUnetHTA Executive Board
Grigorios Agkylalidis	PharmD, Regulatory Affairs Head, Boehringer Ingelheim, Greece
Dimitris Agrafiotis	PhD, Vice President Digital Worldwide Research Development and Medical Affairs, Pfizer
Anna Aletra	Senior Trial Manager, Clinical Development Center Poland, Novo Nordisk
Enrica Alteri	Former head of Safety and Efficacy, EMA
Kostas Athanasakis	Assistant Professor of Health Economics and Health Technology Assessment, Department of Public Health, University of West Attica
Dimitrios Athanasiou	Patient representative at the PDCO
Persephone Augoustidou - Savvopoulou	President, KRIKOS ZOIS Patient Association
Flora Bacopoulou	Assoc. Professor of Pediatrics-Adolescent Medicine, Head of Center for Adolescent Medicine, UNESCO Chair in Adolescent Health Care, 1st Dpt of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, Greece HTA Committee President
Varvara Baroutsou	MD, PhD, GFMD, EMAUD, Consultant Internal Medicine, Pharmaceutical Medicine, President EL.E.F.I., IFAPP President Elect
Andreas Beust	Chief Scientific Officer, GCP-Service International Ltd. & Co. KG
Laura Biven	PhD, Branch Chief for Integrated Infrastructure and Emerging Technologies, Office of Data Science Strategy Division of Program Coordination, Planning and Strategic Initiatives Office of the Director National Institutes of Health
Donato Bonifazi	EPTRI coordinator
Matt Britland	MD, Medical Director, Amgen; President, Australian Pharmaceutical medical and scientific Professionals Association (APPA)
David Brown	Statistician, Medicines and Healthcare products Regulatory Agency (MHRA) MHRA-Licensing
Theodora Calogeropoulou	Research Director Institute of Chemical Biology (ICB), National Hellenic Research Foundation

SPEAKERS' LIST

Clare Campbell	Senior Digital Strategy and Solutions, Labcorp
Athanasios Chaniotis	BSc in Chemistry, Strategic Alliances Manager, J&J Greece
Magda Chatzikou	PhD, Partner PharmEcons Easy Access, SEP Hellenic Open University Health Care Management, Partners at HORIZON 2020 in Healthcare Programme
Jaya Chidambaram	BSc (Hons), MBBS, MRCOphth, PhD, Lead Medical Director, Roche Products Limited, UK
Francis Crawley	BPhil, Executive Director, Good Clinical Practice Alliance (GCPA) & SIDCER
Christina Dalla	PhD, Associate Professor of Pharmacology, Neuropsychopharmacology group, Medical School, National & Kapodistrian University of Athens, President-elect of the Mediterranean Neuroscience Society, Member of the Board of Directors European Brain Foundation
Nikos Dedes	President, Greek Patients Association
Meletios Athanasios Dimopoulos	Hematologist-Medical Oncologist, Chairman of the Department of Clinical Therapeutics, Rector of the National and Kapodistrian University of Athens
Nikolas Dovrolis	MSc, PhD, Post-Doctoral Researcher, Laboratory of Pharmacology, Individualised Medicine & Pharmacological Research Solutions Center (IMPreS), Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece
Victoria Elegant	Adjunct Prof. MBBS, DRCOG, FPM, FFPM, Vice President, Medical Affairs, Amgen Asia Pacific; Global Lead, Access to Medicines, Amgen; President Asia Pacific, Medical Affairs Professional Society Advisor, FPM Global
Eugenia Fouza	PharmD, ex Deputy Head of National Medicines Agency, Pharmaceutical Studies and Research Division
Brigitte Franke-Bray	MD, PhD, FFPM GFMD, Specialist in Pharmaceutical Medicine FMH, Treasurer IFAPP
Shayesteh Fürst-Ladani	MBA, MSc, GFMD, Senior Vice President SFL, Head of SFL Group
Mina Gaga	MD, PhD, Deputy Minister of Health, Ministry of Health, Greece
Ricardo Gaminha Pacheco	Consultant 4SC AG
Silvia Garcia	Senior Manager Regulatory, Drug development & Manufacturing, EFPIA

SPEAKERS' LIST

Silke Gastine	Pharmacometrics Expert, Sanofi, Germany
Jan Geissler	Padvocates, Germany
Evangelos Giamarellos-Bourboulis	MD, PhD, FISAC, Professor of Internal Medicine, Director: Master (MSc) Program of Infectious Diseases, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece
Luca Giraldi	Scientific expert, Data Analytics and Methods Task Force, European Medicines Agency
Georgia Gkegka	PRAC alt. member, Special Scientific Personnel, Pharmacovigilance Department, National Organisation for Medicines, Greece
Ghazaleh Gouya	Priv. Doz. Dr med, Cardiologist, Founder of Gouya Insights, GPMed Board Member and IFAPP Board Member
Achilleas Gravanis	Professor of Pharmacology, School of Medicine University of Crete, Researcher IMBB-FORTH, Affiliated Research Professor, Center of Drug Discovery, Northeastern University, Boston, USA
Melisa Harris	Associate Director Patient Relations, Recruitment, Engagement, Labcorp
Anne-Sophie Henry-Eude	Head of Document Access and Publication Department, EMA
Heidrun Hildebrand	Pediatric Development Alliance Manager, Bayer AG
Peter Hovstadius	MD, PhD, Life Science Consultant, Science Communication Trainer
Kyoko Imamura	MD PhD, DrMedSci, GFMD, IFAPP Past President, Visiting Professor Tokyo University, Japan
Christina Kanaka-Gantenbein	MD, PhD, FMH(CH), Professor of Pediatrics-Pediatric Endocrinology Director, First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital Athens, Greece
Haralambos Karanikas	Assistant Professor, Department of Computer Science and Biomedical Informatics, University of Thessaly, Greece
Sandor Kerpel-Fronius	MD, DSc, FFPM, Semmelweis University, Department of Pharmacology and Pharmacotherapy, Budapest, Hungary
Ingrid Klingmann	MD, PhD, Chairman at EFGCP, President at PharmaTrain Federation, Managing Director at Pharmaplex
Leonidas Klironomos	Pharmacist, MSc (Biostatistics), Acting Head, Clinical Trials Department, Pharmaceutical Studies and Research Division, National Organization for Medicines, Greece

SPEAKERS' LIST

Otmar Kloiber	MD, PhD, Secretary General of the World Medical Association
Olaf Klungel	Professor of Pharmacoepidemiologic Methods, Head of the division of Pharmacoepidemiology & Clinical Pharmacology (PECP), Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, the Netherlands
Theofilos Kolletis	Professor in Cardiology, University of Ioannina, Greece
Christos Kontogiorgis	Associate Professor Health and Environmental Protection, Medical School of Alexandroupolis, Democritus University, ENCePP expert, Greece
Dimitris Kontopidis	Vice President, Greek Patients Association, General Director, Humane Social Enterprise
Evagelia Koraki	President HACRO
Thanassis Kotsanis	Cardiologist, Medical Director GR&CY/ Cluster Medical Director Southern Mediterranean & Black Sea, Bayer AG
Ioannis Kotsiopoulos	Secretary General for Health Services, Ministry of Health, Greece
Katerina Koutsogianni	Former President, Vice President, Greek Patients Association
Stamatiki Kritas	BSc Hons, Business Development Manager, Hellenic Biocluster (Hbio)
Chieko Kurihara	BSocSc, specially appointed Professor, Kanagawa Dental University, and Member of the IFAPP Ethics Working Group
Cordula Landgraf	Director Communication and Stakeholder Engagement, SCTO, Switzerland; Member of IFAPP Board of Officers
Ilhak Lee	MD, PhD, Associate Professor, Department of Medical Law and Ethics, College of Medicine, Yonsei University, Seoul, Korea
Birka Lehmann	Senior Expert for Drug Regulatory Affairs and Lecturer at the University of Bonn, Germany
Adamantia Maniatakou	Chemistry BSc, PhD, Patient Safety Specialist, Deputy of Patient Safety Head, Global Drug Development, Novartis
Vangelis Manolopoulos	Professor, Laboratory of Pharmacology, Medical School, Democritus University of Thrace, and Clinical Pharmacology and Precision Medicine Unit, Academic General Hospital of Evros, Greece
Kotone Matsuyama	JAPhMed Professor, Department of Health Policy and Management, and Vice President of Center for Strategic Research Initiative, Nippon Medical School & IFAPP Ethics Group Chair

SPEAKERS' LIST

Aggelina Mavraki	Clinical Studies' Unit Head, Sanofi Greece
Christoph Meier	MD, Head, Department of Internal Medicine, University Hospital Zürich, Switzerland
Tomas Melvin	Associate Professor of Medical Device Regulatory Affairs, Trinity College Dublin, Ireland
Derick Mitchell	CEO of IPPOSI, Ireland
Annette Mollet	PhD, dipl. Pharm. Med. SwAPP, MBA, Head of Education & Training of the European Center of Pharmaceutical Medicine at the University of Basel, Switzerland
Alex Moulis	PhD, Medical Director, Sandoz
Pantelis Natsiavas	Researcher, Head of eHealth Lab Institute of Applied Biosciences, Centre of Research and Technology Hellas (INAB CERTH), Greece
Markos Ollandezos	Scientific Director, Panhellenic Pharmaceutical Association
Elena Panitti	MD, Global Head RWE Excellence Novartis, Basel, Switzerland
Konstantina Papageorgiou	PhD, Molecular Biologist, Director, Project Delivery, ICON
Andreas Papapetropoulos	BPharm, PhD, FAHA, FBPhS, Professor & Director, Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens; EPHAR Secretary General
Georgios Pappas	Physician, Institute of Continuing Medical Education of Ioannina, Greece
Ioannis Petrovas	BSc Chemistry, EL.E.F.I. Secretary General; Medical Operations Specialist, Medical Dept, AbbVie
Johannes Pleiner-Duxneuner	President, GPMed (Austrian association of Pharmaceutical Medicine)
John Policarpio	Immediate Past President of the Philippine College of Pharmaceutical Medicine and Medical Director at United Laboratories, Inc.
Maria Polydorou	PharmD, MSc Clinical Pharmacy, Director of Pfizer's Pharmacovigilance Departments for Southeastern Europe (Cluster Safety Lead for SEEU)
Lembit Rago	MD, PhD, Secretary General, Council for International Organizations of Medical Sciences (CIOMS), Geneva, Switzerland
Jack Resneck	President of the American Medical Association (AMA)
Marco Romano	MD, PhD, GFMD, IFAPP President

SPEAKERS' LIST

Grigorios Rombopoulos	MD, Specialist in Endocrinology, CSO Novartis Greece
Georgios Rompolas	Cardiologist; Clinical, Regulatory and Medical Director, Novo Nordisk
Mihai Rotaru	Senior Manager Market Access, EFPIA
Eleonora Sarikou	BSc Biology, MBA, Pharmacovigilance & Regulatory Manager, Medical Department GlaxoSmithKline Greece
Veronique Schaaf	Pharmacist, EL.E.F.I. Treasurer
Ali Shehzad	MBBS, MPH, MSc (MStats), PhD, Canada Research Chair in Public Health Economics, Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, Canada; Visiting Associate Professor, University of York, UK; Visiting Associate Professor, Macquarie University, Australia
Effie Simou	Assistant Professor Communication and Mass Media in Public Health, Health Policies, University of West Attika, Athens, Greece
Dominique Sprumont	Prof. University of Neuchatel, Chairman Research Ethics Committee of the Canton of Vaud, Switzerland
Eugena Stamuli	Founding Partner, PharmEcons Easy Access Ltd., Visiting Research Fellow, University of York, UK
Peter Stonier	PhD, FFPM, FMedSci, Director of Specialty Training at the Faculty of Pharmaceutical Medicine, UK
Karthick Sukumaran	Technology Enablement Director Intelligent Safety Automation, Roche
Elyse I. Summers, JD	President and CEO, Association for the Accreditation of Human Research Protections Programs, Inc.
Constantin Tamvakopoulos	PhD, Investigator - Professor Level, Clinical, Experimental Surgery & Translational Research Lab Head, Biomedical Research Foundation of the Academy of Athens
Stefanos Tarazis	MD, PhD, Deputy Head of National Medicines Agency, Pharmaceutical Research & Studies
Nektarios Tavernarakis	Chairman, Foundation for Research and Technology-Hellas; Professor, Medical School, University of Crete; Vice President, European Research Council; Chairman, European Institute of Innovation and Technology
Steffen Thirstrup	European Medicines Agency Chief Medical Officer
George Tousimis	Pharma Innovation Forum, Vice President Greece

SPEAKERS' LIST

Nikos Tsokanas	Medical Digital Lead EMEA, Bayer
Christina Tsouglou	PharmD, Safety Value Partner, Roche Hellas
Kataryna Uspenska	Senior Clinical Project Manager, Gouya Insights
Vera Vazaiou	Senior Manager/Central Monitor Oversight Lead, Amgen
Sriram Venkateswaran	Senior Safety Data Scientist, Roche
Takis Vidalis	PhD, Lawyer, Member of the European Group on Ethics in Science and New Technologies (EGE - European Commission)



ABSTRACT BOOK

www.icpm2022.gr

icpm

ABSTRACT BOOK

PHARMACEUTICAL MEDICINE

EDUCATIONAL PROGRAM TO BRAZILIAN PARLIAMENT DURING COVID-19 PANDEMIC

H.G. Osmo¹, E.F. Motti², C. Schmidt³, M.V. Lima⁴, S.M. Dainesi¹

OP01

¹Brazilian Association of
Pharmaceutical Medicine
(SBMF)

²GFMD, Trials & Training
Consult

³Tigermed Latin America

⁴GFMD, Blau Farmacêutica

The Covid-19 Pandemic in 2020 and 2021 mobilized the society and caused a sudden change in the common life from a social, economic and political point of view. The topic became a major subject in discussions involving politicians, journalists and other professionals. Long reports occupied space in the media. A great gap in knowledge about the development of vaccines and drugs in general, from the preclinical phases to access, was observed. The misinformation and preconceptions about the role of the Pharmaceutical Industry in society became a theme that needed to be urgently clarified. Based on that, SBMF organized a course “Connection with the Parliament for Development”, with the support of Interfarma (Association of Brazilian Research Based Industries) and the Brazil - US Business Council. This initiative was tailored for politicians elected and present in the Parliament. Five virtual sessions were planned, every 15 days: 1) From the discovery of new molecules to the regulatory approval; 2) Ethics and regulatory environment; 3) Innovation and intellectual property; 4) Regulatory rigor and safety; 5) Access to medicines in Brazil.

The general population had little knowledge about the main steps needed before authorization to commercialize medicines: the importance of good manufacturing practices in the quality of medicines, the quality of clinical research, from ethical procedures to analysis of results. International and national laws on research ethics and the involvement of regulatory agencies were exposed. The accelerated process of vaccine approval in the exceptional case of COVID-19 pandemic was also addressed. The process of incorporation of drugs into the Brazilian Health System (SUS), the pricing definition, budget impact analysis, and general concepts of access and regulation were explained.

This initiative led by SBMF and Interfarma contributed to increase the transparency of the way medicines and vaccines are developed. Other courses like this were recommended, aimed mainly for journalists and lay public, for elucidation of several little-explored aspects in the development of medicines.

ABSTRACT BOOK

PHARMACEUTICAL MEDICINE

RESULTS OF THE FIRST EDITION OF A MEDICAL INFORMATION IN THE PHARMACEUTICAL INDUSTRY UNIVERSITY EXPERT COURSE IN SPAIN

Lo Re Daniele

OP02

Medical Affairs Chiesi
Spain

The MI Working Group (MIWG) of AMIFE (Spanish Association of Medicine of Pharmaceutical Industry) and the University San Pablo-CEU (Madrid) implemented the first postgraduate course on medical information (MI) in pharmaceutical companies (PC) in Spain to close the training gap identified among the MI professionals [1,2] and as an option for graduates with health sciences profile interested in the MI area in PC.

The course, organized into 9 modules, finished in May 2022, and consisted of 100 hours of formal classes, 3 days a week from 5:30pm-8:30pm, both online and face to face, taught by members of the MIWG-AMIFE (n=14) and other prestigious professionals (n=13) in the fields of searching, communicating and analyzing scientific/medical data. Students could apply for 3 months of optional internship in MI areas of PC. Members of MIWG-AMIFE had the option to choose to attend only selected modules.

In total, 20 people from 3 different countries registered and attended the entire course (15 professionals in PC, 1 documentalist and 4 health science graduates). Additionally, 11 MI professionals chose to attend 3 specific modules. All students attended at least 80% of required classes [media (range)]: 93% [80%-100%], and 100% responded the questionnaires submitted to evaluate them. Participants rated 5 (highest score): content structure [media (range)]: 62% [50%-79%], usefulness of training material: 59% [45%-71%], lesson utility: 61% [48%-79%] and teachers' communication skills: 67% [57%-83%]. Five students applied for internships. As positive aspects of the course, participants highlighted: confidence, motivation, and knowledge; they suggested to increase practical work vs. theory classes.

The success of the course encourages to MIWG-AMIFE to plan new editions in which to implement the suggestions proposed by the participants in this first edition.

Reference

1. Flores A, et al. *DIA Congress 2015 Nov 10-11; London, UK.*
2. Flores A, et al. *EPI 2021;30(3).* <https://doi.org/10.3145/epi.2021.may.10>.

ABSTRACT BOOK

PHARMACEUTICAL MEDICINE

THE IMPORTANCE OF LATIN AMERICA IN GLOBAL CLINICAL TRIALS: EXPANDING CLINICAL RESEARCH BEYOND BORDERS

Marlene Teresa Llópiz Avilés

OP03

Global Oversight Director
for PPD

The dramatic increase in globalization—especially into conducting more trials in Latin America (LATAM)—may be attributed to greater competition in the USA and European markets; costs, patient recruitment, as well as looking for specific therapeutic indications and the demand for qualified clinical research professionals. The rapid economic growth and improved regulatory processes in emerging and growing regions, partly driven by wider adoption of ICH guidelines and principles are important factors considered.

LATAM has again come into the limelight for pharmaceutical, biotechnological and device studies. Biopharmaceutical and especially biotechnological companies have uncovered new opportunities in Central American, Caribbean, and South American countries.

The current population of Latin America and the Caribbean is 665,407,471, based on the latest United Nations estimates. LATAM and the Caribbean population is equivalent to 8.42% of the total world population. LATAM provides a large drug-naïve patient population with common and specific disease profiles, rapid compliant patient recruitment, motivated and experienced investigators, and USA and EC-equivalent medical standards, as well as highly trained monitoring and project management teams on GCP and ICH guidelines.

Partnering contract research organizations, regulatory businesses, patient recruitment companies and participating NGOs have contributed to conducting international global trials in LATAM. Conducting studies in LATAM provides sponsors with an array of countries for testing drugs, reduced costs for strategic multicenter studies, credible and objective submittals, and highly professional staff members at CROs who are bilingual, graduated in allied health and medical fields, often trained in the USA and Europe.

Large, urban populations in LATAM enable faster enrollment and easier patient follow-up. These populations often see clinical trials as viable healthcare options for gaining access to free medication and closely supervised and specific health care, which leads to high patient retention rates. Quality of data collected is comparable to that from any other country. LATAM is a viable and convenient option for global clinical trial conduction from the “get go”.

ABSTRACT BOOK**REGULATORY SCIENCE, REGULATORY AFFAIRS,
ETHICAL, LEGAL, SOCIAL RELATED ISSUES****POST-TRIAL RESPONSIBILITIES, 15 YEARS OF DISCUSSION**

Sonia Mansoldo Dainesi

OP04

**Brazilian Association of
Pharmaceutical Medicine
– SBMF**

The first request in Brazil for a post-trial access to an investigational medicine was received in 2005 from National Ethics Committee, who required that a new insulin just evaluated in a multicentric international trial should be made available for the patients who still needed the treatment after the end of the study. It appears obvious that if the patient has benefit with the new drug, the treatment should continue. However, how to safely continue the treatment outside of a clinical research environment? How can you be sure the risk does not outweigh the benefit? For how long should the drug be provided? Who would be responsible for monitoring the patients if the trial was closed? Would off-label use be encouraged with this procedure?

The first publications regarding drug access after clinical studies were related to HIV trials conducted in Africa. Vulnerability of study participants was the big concern. The clinical research participation of Brazil sites in multinational trials was growing and this made the issue gain relevance in the country, becoming a valuable case study. Many international and national legislations mentioned the theme but without clarity, leaving room for misinterpretation. Since then, post-trial access has been discussed in some international panels by all clinical research stakeholders (investigators, sponsors, ethics committees, regulatory agencies, and patients). Continued access to experimental medications is indeed one way in which subjects may benefit from research participation but only furnish the drug is not enough. Medical care and follow-up are necessary, creating an additional burden to investigators and institutions, and more important, a confusion between research and clinical care. The evolution of this debate helped us to clarify that, before starting a trial, arrangements should be agreed, in order to plan a responsible transition to clinical care at the end of the research and, in some specific cases, access to the drug must be ensured if no treatment alternatives exist. The debate is still open.

ABSTRACT BOOK

PATIENT CENTRICITY IN RESEARCH & DEVELOPMENT AND HEALTH TECHNOLOGY ASSESSMENT

ACCESS TO PEDIATRIC/ADOLESCENT MEDICINAL PRODUCTS IN GREECE

A. Margetis¹, C. Kani¹, A. Chantzaras¹, V. Koutsouris², F. Bacopoulou¹

OP05

¹Health Technology
Assessment and
Reimbursement
Committee, Ministry of
Health, Athens, Greece
²Ministry of Health,
Athens, Greece

Background: Access to treatment plays a major role in the provision of quality healthcare. The purpose of the present study was to examine the proportion of applications of medicinal products with pediatric/adolescent vs. adult indications, for inclusion in the Positive Reimbursement List in Greece, during a 4-year period, from 2018 to 2021.

Methods: Data were collected from the European Medicines Agency (EMA) and the Greek Ministry of Health websites, as well as from the Greek Health Technology Assessment (HTA) Committee's database. The dataset included all the medicinal products which received marketing authorization/extension of indication during the study period. Percentages of products with pediatric/adolescent indications were calculated according to their marketing authorization date, their submission to the Greek HTA Committee and their inclusion in the Positive Reimbursement List.

Results: Among 598 centrally authorized medicinal products/or extended indication products by EMA, 35.6% (n=213) included a pediatric/adolescent indication and 64.4% (n=385) were indicated for adults. Only 20.2% (n=43) of all centrally approved medicinal products with a pediatric/adolescent indication had been submitted to the HTA Committee by the end of the study period, from which 25.6% (n=11) have been included in the Positive Reimbursement List. In contrast, 37.9% (n=146) of all products which received marketing authorization or indication extension through the EMA for adults had been submitted to the HTA Committee by the end of the study period, from which 37% (n=54) have been included in the national Positive Reimbursement List.

Discussion: As expected, a greater proportion of medicinal products have been authorized for adults than for younger patients. Furthermore, HTA submission and reimbursement rates are lower for medicinal products authorized for children and adolescents than for adults. The needs of the pediatric/adolescent population should be taken into account in the marketing authorization procedure as well as in the overall HTA process.

ABSTRACT BOOK

PATIENT CENTRICITY IN RESEARCH &
DEVELOPMENT AND HEALTH TECHNOLOGY ASSESSMENTEVALUATION OF CONSUMERS' KNOWLEDGE, BELIEFS AND RISK
ASSESSMENT REGARDING PROTEIN

Paraskevi Basdeki¹, Yiota Athanassopoulou¹, Georgia-Eirini Deligiannidou¹,
Diamanto Lazari², Christos Kontogiorgis¹, Theodoros Constantinides¹

PP01

¹Laboratory of Hygiene and
Environmental Protection,
Democritus University of
Thrace, Alexandroupolis,
Greece

²Department of
Pharmacognosy-
Pharmacology, School
of Pharmacy, Faculty of
Health Sciences Aristotle
University of Thessaloniki,
Thessaloniki, Greece

Background: Protein supplements are consumed both by amateur and professional athletes. However, amateur athletes' knowledge, motivations, occurrence of consumption, benefits and potential health risks need to be investigated.

Objectives: This study investigates the state of protein supplements use among athletes in Greece and the sources of information, reasons of consumption and motivation and frequency of use.

Methods: The research was based on a survey. 928 people of random gender and age, of different athletic activities, from all around Greece participated. The questionnaire was shared anonymously both in person and online, mainly on gyms and other athletic fields. It consisted of 37 questions, on demographics, sources of information, regularity of use, purchasing habits, associated risk knowledge and beliefs on supplements. The data were categorized, analyzed using SPSS v15.0.

Results: Most responders were females 64.7% of mean age 27.7 years, whereas males were 35.3% of mean age 29.3 years, respectively. Mainly, they had a normal body mass index (BMI) (66.4%) and an educational level of BSc or higher (61.8%). A quarter of the participants, (24.8%) were consuming protein supplements and the majority were men. The main factor of use was the real action of this product, that means raise muscle mass (60%). In addition, users of protein supplements followed essentially Mediterranean diet (32.4%), while they also consumed other supplements such as vitamins, amino acids, carbohydrates, and creatine supplements. It was found that the most common source of information was the internet (70.4%), whereas 59.6% of consumers considered them as safe and of good quality and 47% of them preferred purchasing online due to lower costs. Regarding the form of protein supplements, powder was the first choice (90.9%). Furthermore, half of users utilized the supplements more than 2 times per week and after exercise. Finally, side effects have been observed in 6.3% of consumers.

ABSTRACT BOOK

PATIENT CENTRICITY IN RESEARCH & DEVELOPMENT AND HEALTH TECHNOLOGY ASSESSMENT

PP01

Conclusions: Because of inappropriate information and products' wrong labelling, the majority of youth might be led to unwanted results with the consumption of protein supplements. That is why further education of athletes and coaches for responsible purchasing and use would be necessary.

ABSTRACT BOOK

PHARMACEUTICAL MEDICINE

HOW THE PHARMACEUTICAL MEDICINE WORLD WAS AFFECTED BY
THE COVID-19 PANDEMIC: A LOOK BACK

Marlene Teresa Llópiz Avilés

PP02

Global Oversight Director
for PPD

On March 11th, 2020, the World Health Organization (WHO) announced the start of a pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus and disease were first identified in December 2019 in Wuhan, China – spreading rapidly worldwide.

The number of cases and deaths continued to rise rapidly in the following months, requiring countries to respond in an escalated way, as well as take action as soon as possible. Such actions were to help delay the pandemic, giving healthcare systems time to prepare and assimilate the impact. However, the virus was much faster and rampant.

Irrespective of the disease's trajectory in each country, there were several actions that needed to be taken. There was no one-size-fits-all approach across the world. The past two years have been full of incongruities occurring at all levels of health organizations, companies, governments, people, paradoxes and absurdities. Was / is COVID-19 a common enemy? Are we still at its mercy? In some ways it is or has been, and we are somewhat still at its mercy. However, each country has approached the pandemic differently, following their own timelines; facing difficulties with previously established budgets; and tackling the problem as swiftly as possible—although they had never contemplated or experienced this emergency. Was/is there worldwide solidarity? Were the pharmaceutical companies part of that solidarity? It is often said that confusion is often but a first step towards clarity. The world is/was/has been confused. Are we still confused? Have all our questions been answered? Far from it.

This presentation will cover the changes that were required to be made by the pharmaceutical medicine world in terms of the pandemic and how our lives have been at COVID-19's mercy and spread. It will also include a look at returning to "normality" —from home-based offices, family tragedies and losses, adjusting to new modalities of lifestyles and communications to hybrid conferences and meetings, companionship and new work scenarios. Included also will be pharmaceutical medicine development, vaccine strategies, worldwide collaborations, and continuous unity for a better place and life and overcoming an enemy never thought would exist.

ABSTRACT BOOK

PATIENT SAFETY & PHARMACOVIGILANCE

FIRST-LINE TREATMENTS FOR KIDNEY CANCER AND SECOND-LINE TREATMENTS FOR UROTHELIAL CANCER: SYSTEMATIC REVIEW, META-ANALYSIS OF SAFETY, COST ANALYSIS

K.A. Nikolaou¹, C. Kani², F. Bacopoulou^{2,3}, S.L. Markantonis¹

OP06

¹Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece

²University Research Institute of Maternal and Child Health & Precision Medicine, and UNESCO Chair in Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

³Center for Adolescent Medicine and UNESCO Chair in Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Background: Immune checkpoint inhibitor (ICI) combinations are currently first-line treatment options for clear-cell renal cell carcinoma (ccRCC). Moreover, ICIs are recommended for platinum-refractory urothelial carcinoma (PRUC). ICIs have been associated with a new type of toxicity, immune-related adverse events (AEs).

Aim: To compare the safety of first-line treatments for ccRCC and second-line ICIs versus chemotherapy for PRUC. Also, to estimate the economic impact of first-line ICI combinations for ccRCC, on the Greek National Health System (ESY).

Methods: CENTRAL, PubMed and clinicaltrials.gov were searched to identify randomized controlled trials (RCTs) with safety outcomes for the treatments studied. Review Manager software was used for statistical analysis. For the economic analysis, data were collected from the Price Bulletin of Medicines for Human Use.

Results: Nine RCTs were selected for the systematic review of ccRCC and two for the systematic review of PRUC. The meta-analysis of first-line treatments for ccRCC suggests that ICI combinations have a lower risk of “treatment-related AEs” than sunitinib (OR=0.53, 95%CI:0.38-0.73). The meta-analysis of second-line regimens for PRUC suggests that ICIs have a lower risk of “AEs” than chemotherapy (OR=0.32, 95%CI:0.17-0.60). The economic analysis estimated that pembrolizumab+axitinib included an additional cost of 55,154.74€ per patient per year compared with nivolumab+ipilimumab, for first-line treatment of patients with ccRCC, and an additional cost of 64,575.65€ per patient for the median progression-free survival of each treatment for the intermediate- and poor-risk population.

Conclusions: First-line regimens for ccRCC that include ICIs seem to have a lower risk of AEs than sunitinib. The ICIs, atezolizumab, pembrolizumab, seem to have a lower incidence of toxicity than chemotherapy in patients with PRUC, but more studies need to be conducted for safer conclusions. ESY expenditure seems to be lower with nivolumab+ipilimumab compared to pembrolizumab+axitinib for patients with ccRCC, without taking into account rebates applied.

ABSTRACT BOOK

PHARMACEUTICAL MEDICINE

EARLY SELECTION OF ORAL FORMULATION ACCEPTABILITY WITH A SCIENTIFICALLY SOUND COMPOSITE ENDPOINT ASSESSMENT METHOD – AN EFFICIENT STRATEGY TO OPTIMIZE PAEDIATRIC MEDICINES DEVELOPMENT

Viviane Klingmann¹, Sibylle Reidemeister², Ingrid Klingmann³, Manfred Wargenau⁴

OP07

¹Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany

²Novartis Pharma AG, Global Drug Development / Technical Research & Development, Basel, Switzerland

³Pharmaplex bv, Wezembeek-Oppem, Belgium

⁴M.A.R.C.O. GmbH & Co. KG, Institute for Clinical Research and Statistics, Düsseldorf, Germany

Introduction: Paediatric medicine development needs to be facilitated and shortened. Justification of the formulation selection is a challenging element in paediatric development negotiations with authorities as no—scientifically sound, with broadly recognised acceptability—assessment methods exist.

Objective: Enabling frontloading of oral formulation selection with a standardised, statistically sound acceptability assessment method before entering the paediatric efficacy and safety studies.

Methods: In statistically powered paediatric patient studies with placebo-containing oral formulations, performed with standardised investigator-observed assessment methods and defined evaluation criteria for swallowability and palatability in children, statistically significant differences between the acceptability of several oral formulations were detected (Klingmann et al. [1-6]). To further strengthen discrimination, a new composite endpoint acceptability method was established combining a deglutition score and palatability assessment. The data from studies [5,6] investigating mini-tablets, oblong tablets, orodispersible films and syrup were used to evaluate the suggested acceptability assessment tool for the composite endpoint and to demonstrate its validity, expediency and applicability. A factor analysis was applied for each formulation and the results for acceptability defined as composite endpoint were calculated for the different formulations. Each outcome category of acceptability was then related to the outcome of the factor analysis as expressed by the linear combination for the main component.

ABSTRACT BOOK

PHARMACEUTICAL MEDICINE

OP07

Results: A high association between acceptability categories and the results from factor analysis was recognized. Comparison of the acceptability categories with regard to the main component by analysis of variance yielded a p-value < 0.0001. All formulations showed highly consistent results.

Conclusion: The suggested acceptability as composite endpoint can be regarded as a valid approach representing the result of the factor analysis and providing high validity and reliability of the suggested approach for assessing acceptability as composite endpoint. It is highly suitable and efficient to select different preferences of oral formulations before entering indication-specific efficacy or safety studies.

References

1. Spomer N, Klingmann V et al., *Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study*, Arch Dis Child, 2012; 97:283-286.
2. Klingmann V et al., *Favourable acceptance of mini-tablets compared to syrup: a randomised controlled trial in small children*, J Pediatr, 2013; 163:1728-1732.
3. Klingmann V et al., *Acceptability of uncoated mini-tablets in neonates - a randomized controlled trial*, J Pediatr, 2015;167:893-896.
4. Klingmann V et al., *Acceptability of multiple uncoated mini-tablets in infants and toddlers: A randomized controlled trial*, J Pediatr, 2018; 201:202-207.
5. Klingmann, V et al., *Acceptability of an orodispersible film compared to syrup in neonates and infants: A randomized controlled trial*. Eur J Pharm Biopharm, 2020; 151:239-245.
6. Münch J et al., *Acceptability of Small-Sized Oblong tablets in Comparison to Syrup and Mini-tablets in Infants and Toddlers: A Randomized Controlled Trial*. Eur J Pharm Biopharm, 2021; 166:126-134.

ABSTRACT BOOK

REGULATORY SCIENCE, REGULATORY AFFAIRS,
ETHICAL, LEGAL, SOCIAL RELATED ISSUES

GAPS AND CHALLENGES RAISED BY THE DIGITAL TECHNOLOGY USE IN THE PHARMACEUTICAL INDUSTRY

Georgia Livieri^{1,4}, Eleni Mangina², Evangelos Protopapadakis³, Andrie Panayiotou⁴

OP08

¹Ethics Research
Associate, Cardiovascular
Epidemiology and Genetics
Research Lab

²College of Science, UCD
College of Science, Dublin,
Ireland

³National and Kapodistrian
University of Athens,
Faculty of Philosophy,
Athens, Greece

⁴Cyprus International
Institute for the
Environmental and Public
Health, Faculty of Health
Sciences, Limassol, Cyprus

Pharmaceutical companies have been challenged either with regards to the rising development costs or the satisfaction of the need to discover new approaches in differentiating the candidate drugs. Digitalization has been spreading with a rapid pace throughout Europe affecting both healthcare and pharmaceutical sectors. Recent advances in digital health technology, including wearables, sensors, in-home clinical devices, have given space to several data endpoints leading these devices to be proved as a valuable tool in clinical trials' programs of the modern era. Specifically, vast amounts of data are being collected, processed and analyzed, coming either from the phase of development and production of medicines or from patient treatments and its subsequent outcomes. Due to covid-19 pandemic and social distancing measures, a huge demand in alternatives for in-person care, including virtual trials, telemedicine and remote patient monitoring, has been promoted, as multiple stakeholders seemed to be benefited at a wide range. Therefore, there is an urgent need for the "capitalization" of pharma industry in the new digital era of healthcare and for the integration of digital technologies across its value chain, contributing to the overall support of its clients. However, several issues, emerging from the digital transformation in healthcare, need to be tackled. Despite the offered opportunities, this study aims to address the gaps and challenges raised by the digital technology use in drug developers, being gathered from a philosophical perspective.

ABSTRACT BOOK

RWD / REAL WORLD EVIDENCE/ BIG DATA / PHARMACOEPIDEMOLOGY

REAL-WORLD DATA STUDY ON THE USE OF PSYCHIATRIC DRUGS IN GREECE: INVESTIGATING THE IMPACT OF COVID-19 PANDEMIC IN MENTAL HEALTH

Foteini Dermiki-Gkana, Panagiotis Nikolaos Lalagkas, Christos Kontogiorgis,
Theodoros Constantinides

OP09

Laboratory of Hygiene and
Environmental Protection,
Department of Medicine,
Democritus University of
Thrace, Alexandroupolis,
Greece

Background: The outbreak of COVID-19 pandemic had a severe psychological impact on the Greek population due to the fear of COVID-19 disease, death, the social isolation, and the extended periods of quarantines during the period 2020-2021.

Aim: The significant negative impact of COVID-19 pandemic crisis on the mental health of Greeks has enforced the execution of a study focusing on psychiatric drugs' (antidepressants (N06A), anxiolytics (N05B) and hypnotics/sedatives (N05C)) consumptions and the investigation of the mental disorders being responsible for this.

Methods: We analyzed community pharmacies' sales data of 31 psychiatric medicines, provided by the IQVIA HELLAS database, to calculate their annual consumption for the years 2019 and 2020, expressed in "Number of Daily Doses (DDDs) per 1,000 inhabitants per day". Furthermore, for the same time period, we estimated their use per diagnosis of mental disorder (ICD-10 codes) using the National Organization of Health Care Provision (EOPYY) database.

Results: The consumption of antidepressants, anxiolytics and hypnotics/sedatives increased in 2020 compared to 2019 by 7.2%, 8.1% and 2.6%, respectively. In 2020, the highest use (51,6 DDDs/1,000 inhabitants/day) was observed for the selective Serotonin Reuptake Inhibitors (N06AB) and more specifically for the active substance escitalopram (N06AB10). Regarding anxiolytics, benzodiazepines (N05BA) showed the highest consumption (37.3 DDDs/1,000 inhabitants/day) in 2020. Alprazolam (N05BA12) was the most widely prescribed medicine and recorded an increase of 13,6% from 2019 to 2020. Furthermore, by analyzing the reason of these psychiatric drugs' prescriptions, it was found that Depressive disorders F32 and F33, Other anxiety disorders (F41) and Sleep disorders not due to a substance or known physiological condition (F51) were the most common diagnoses on the prescriptions of psychiatric drugs. Finally, the number of patients with Anxiety disorders (F41), who received anxiolytics and sedatives/hypnotics was increased 5% and 3% respectively from 2019 to 2020.

Conclusions: We observed an increasing trend in the consumption of antidepressants, anxiolytics, and hypnotics/sedatives during the COVID-19 pandemic (2020) compared to pre-pandemic period (2019). Moreover, we observed that four mental disorders were the main reason for the higher consumption of psychiatric medicines.

ABSTRACT BOOK

TRANSLATIONAL RESEARCH & PRECISION MEDICINE

VALUE CREATION IN CELL AND GENE THERAPIES FROM A HEALTH-ECONOMIC PERSPECTIVE

Daniela Fazzotta, Thomas D. Szucs, Annette Mollet

OP10

Faculty of Medicine,
University of Basel,
Switzerland

Background: Cell and gene therapies (CGTs) are highly specialized one-time technologies with curable potential targeting rare diseases, previously difficult-to-treat, or untreatable diseases.

Objective: The scope of this study was to promote objective value assessment of CGTs by investigating three rare diseases: spinal muscular atrophy (SMA), hemophilia A (Hem A), and sickle cell disease (SCD).

Methods: A systematic review of reports published between January 1, 2000, and September 30, 2021, was conducted on PubMed. For the set criteria 25 eligible studies on 17 interventions were found.

Results: Hem A with inhibitors (for patients developing inhibitors against rFVIII) reported the highest SOC costs: While lifetime cost-estimates per patient reached up to USD 99.21 million for SOC with BPA Prophylaxis (at 21.28 LYs, 15.21 QALYs), they were only USD 9.27 million for intervention with Hypothetical Gene Therapy (at 21.28 LYs, 15.41 QALYs), generating per-patient-cost-savings of roughly USD 90 million in favor of the US health system. Cost-savings per patient without inhibitors were less but still reached up to roughly USD 9.8 million (rFVIII Prophylaxis \$23.47m vs \$13.69m for Valoctogene Roxa-parvovec gene therapy [at 23.56 LYs, 17.31 QALYs vs 26.53 LYs, 19.09 QALYs, respectively]). Similarly, in SCD the per-patient cost-savings with CGTs reached up to roughly USD 6.4 million (Hydroxyurea \$8.75m vs \$2.37m hypothetical gene therapy [at not reported LYs/QALYS vs 26.4 LYs, 29.9 QALYs for gene therapy]). Finally, in SMA, CGTs generated cost-savings of roughly up to USD 2.4 million per patient (Nusinersen \$6.32m vs \$3.93m gene therapy Onasemnogene Apeparvovec [at 7.11 LYs, 5.29 QALYs vs 20.09 LYs, 13.33 QALYs, respectively]), see Table 1.

Conclusion: The results demonstrate that CGTs are significantly less expensive (up to \$90m per-person) compared to lifelong chronic SOC treatments while generating significantly more health gains (SMA: +14.18 LY/+12.18 QALYs, BSC vs Onasemnogene).

ABSTRACT BOOK

PATIENT CENTRICITY IN RESEARCH
& DEVELOPMENT AND HEALTH TECHNOLOGY ASSESSMENT

MEDICINAL PRODUCTS ASSESSED BY THE HEALTH TECHNOLOGY ASSESSMENT COMMITTEE IN GREECE OVER 4 YEARS (2018-2022)

A. Chantzaras¹, A. Margetis¹, C. Kani¹, V. Koutsouris², F. Bacopoulou¹

PP03

¹Health Technology Assessment and Reimbursement Committee, Ministry of Health, Athens, Greece

²Ministry of Health, Athens, Greece

Objectives: The purpose of the present study was to evaluate the type of medicinal products and the pace of recommendations issued by the Health Technology Assessment (HTA) Committee in Greece over 4 years, from its establishment in 2018 until 2022.

Methods: Data regarding new medicinal products/extensions of indications were collected from the HTA Committee's database and other publicly available sources. Analyses were carried out with respect to the legal basis of approval of the medicinal products. A secondary analysis by ATC1 level was also performed.

Results: During the study period, 140 new active substances, 37 orphan medicinal products, and 44 vaccines/biosimilars were submitted to the Greek HTA Committee. Another 92 applications referred to known/well established/hybrid products, whereas 36 applications pertained to fixed combinations. Most medicinal products belonged to the category of anti-neoplastic and immunomodulating agents (ATC-1 L) (25.98%) followed by alimentary tract and metabolism agents (ATC-1 A) (14.2%). Total recommendations during the study period were 216 (36.1%, 29.2%, 18.1%, 10.6%, and 6%, for new active substances, known/well established/hybrid products, biosimilars/vaccines, fixed combinations, and orphans, respectively).

Conclusions: The majority of HTA recommendations referred to new active substances, with antineoplastic and immunomodulatory effects. These findings corroborate the products' assessment plan outlined in the European HTA regulation and underline the emergence of the new era of immuno/oncology treatments.

ABSTRACT BOOK

TRANSLATIONAL RESEARCH & PRECISION MEDICINE

HEALTH TECHNOLOGY ASSESSMENT OF TWO CAR T-CELL-BASED THERAPIES, TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL, FOR THE TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND RELAPSED OR REFRACTORY LYMPHOMAS

M. Kokkali¹, A. Tsonis¹, C. Kani², F. Bacopoulou^{2,3}, S.L. Markantonis¹

PP04

¹Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece

²University Research Institute of Maternal and Child Health & Precision Medicine, and UNESCO Chair in Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

³Center for Adolescent Medicine and UNESCO Chair in Adolescent Health Care, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Background: Most European countries have adopted Health Technology Assessment (HTA) practices to support decision-making processes in health care at a policy level. Two CAR T-cell therapies have been recently approved in Greece for the treatment of patients with acute lymphoblastic leukemia (ALL) and relapsed or refractory lymphomas (DLBCL, PMBCL), tisagenlecleucel and axicabtagene ciloleucel.

Aim: To study the phase III clinical trials on which the approval of the CAR T-cell therapies was based, and critically evaluate the benefits and risks of both treatments. Also, to estimate the total cost of CAR T-cell treatment in Greece and review reimbursement schemes, proposed or implemented by health organizations worldwide, and to propose a suitable reimbursement model for Greece.

Methods: Efficacy and safety data on tisagenlecleucel and axicabtagene ciloleucel from EMA evaluation reports and published clinical trials were collected. Completed studies were assessed for the magnitude of clinical benefit of each therapy (ESMO-MCB scale) and the risk of bias (Cochrane Collaboration tool). Finally, the cost of each therapy was estimated.

Results: Only 7 of the 49 clinical trials found in the literature had published results. ALL patients showed a positive response to treatment (ORR 33.9%-81.3%), but ultimately the magnitude of the clinical benefit was moderate (Grade 2) and the clinical trials were of low quality. The cost of therapy per patient for ALL with tisagenlecleucel, and DLBCL or PMBCL with axicabtagene ciloleucel, was estimated to be high, but comparable (295,282.47€ and 286,260.78€, respectively). The lowest cost was for DLBCL treatment with tisagenlecleucel (278,815.24€).

ABSTRACT BOOK

Conclusion: Both CAR T-cell therapies provide an important actual clinical benefit and a moderate improvement in added benefit over conventional chemotherapy regimens. Outcomes-based staged payments, in line with other European countries, may be the most acceptable reimbursement approach for these therapies in Greece. Despite their high cost these health benefits might be cost effective.

AUTHORS' INDEX

ATHANASSOPOULOU Y. **PP01**

BACOPOULOU F. **OP05, OP06, PP03, PP04**

BASDEKI P. **PP01**

CHANTZARAS A. **OP05, PP03**

CONSTANTINIDES T. **PP01, OP09**

DAINESI S.M. **OP01, OP02**

DANIELE L. R. **OP03**

DELIGIANNIDOU G.-E. **PP01**

DERMIKI-GKANA F. **OP09**

FAZZOTTA D. **OP10**

KANI C. **OP05, OP06, PP03, PP04**

KLINGMANN I. **OP07**

KLINGMANN V. **OP07**

KOKKALI M. **PP04**

KONTOGIORGIS C. **PP01, OP09**

KOUTSIOURIS V. **OP05, PP03**

LALAGKAS P. N. **OP09**

LAZARI D. **PP01**

LIMA M.V. **OP01**

LIVIERI G. **OP08**

LLÓPIZ AVILÉS M.T. **OP03, PP02**

MANGINA E. **OP08**

MARGETIS A. **OP05, PP03**

MARKANTONIS S.L. **OP06, PP04**

MOLLET A. **OP10**

MOTTI E.F. **OP01**

NIKOLAOU K.A. **OP06**

OSMO H.G. **OP01**

PANAYIOTOU A. **OP08**

PROTOPAPADAKIS E. **OP08**

REIDEMEISTER S. **OP07**

SCHMIDT C. **OP01**

SZUCS T.D. **OP10**

TSONIS A. **PP04**

WARGENAU M. **OP07**

CONFERENCE ORGANISER

M I N D  V I E W

www.icpm2022.gr

icpm